COVID-19与异性造血干细胞移植后的并发症有关
Qi Wen1, Ze Guo1, Xiao-Hui Zhang1
1Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
在COVID-19感染的过程中,
科学领域:
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
- 在瘤学瘤学.
背景情况:
- 全源性造血干细胞移植 (allo-HSCT) 是一种复杂的程序,可能会出现并发症.
- COVID-19 感染可能会影响患者在 allo-HSCT 后的结果.
研究的目的:
- 研究COVID-19感染严重程度和持续时间对移植后并发症的影响.
- 为了确定COVID-19的alo-HSCT接受者的不良结果的风险因素.
主要方法:
- 对接受allo-HSCT的179名住院COVID-19患者的回顾性分析.
- 根据COVID-19感染持续时间 (短期≤18天与长期>18天) 来对患者进行分类.
- COVID-19严重程度的分类 (不严重与严重感染).
主要成果:
- 长期的COVID-19感染与较高的不良移植功能 (PGF),细胞大脑病毒 (CMV) 肺炎和非复发性死亡率 (NRM) 相关.
- 严重的COVID-19感染与增加的CMV肺炎和NRM有关.
- 长期和严重的感染与较低的整体存活率 (OS) 相相关.
结论:
- COVID-19的严重程度和持续时间是影响allo-HSCT后并发症和结果的重要因素.
- 感染持续时间会影响PGF,而严重程度会影响NRM和OS.
- 这些发现凸显了管理COVID-19在All-HSCT接受者的重要性.
更多相关视频
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
相关概念视频
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Regulation of Hematopoietic Stem Cells
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Cell-mediated Immune Responses
